Proposes to amend language relative to pharmaceutical access, costs and transparency.
Proposes pharmaceutical manufacturers to have an early notification requirement for pipeline drugs, generic drugs, or biosimilar drugs. Failure to provide an early notification may impose appropriate sanctions against the manufacturer, including reasonable monetary penalties not to exceed $500,000, in each instance. Proposes the commission shall conduct a review of eligible drugs, which may involve requiring a disclosure from the manufacturer regarding pricing.